Akash Patnaik

Akash Patnaik has applied cfDNA fragmentomics to monitor treatment response in castration-resistant prostate cancer, demonstrating that fragmentation pattern changes precede radiographic response assessment by weeks. His work on integrating cfDNA fragmentation with androgen receptor pathway analysis has provided insights into resistance mechanisms to hormonal therapies. His research on epigenetic features extractable from cfDNA fragments has expanded the clinical utility of fragmentomics beyond cancer detection to therapy selection.